sorafenib has been researched along with ethanolamine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ethanolamine) | Trials (ethanolamine) | Recent Studies (post-2010) (ethanolamine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,212 | 12 | 350 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B | 1 |
1 other study(ies) available for sorafenib and ethanolamine
| Article | Year |
|---|---|
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Chaperonins; Computational Biology; Computer Simulation; Databases, Genetic; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Ethanolamine; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; HSP90 Heat-Shock Proteins; Humans; Liver Neoplasms; Male; Molecular Chaperones; Niacinamide; Niclosamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Time Factors; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |